← All trials
NCT05212116
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 16, 2021
- Primary completion
- Mar 11, 2022
- Completion date
- Mar 11, 2022
- First posted
- Jan 27, 2022
- Last posted
- Apr 22, 2022
- Enrollment
- 0
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- SyndesiLead sponsor
- University of OxfordOverall official - principal investigator
- P1vital LimitedCollaborator
- SyndesiStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.